The Multiple Myeloma Research Foundation (MMRF) today announced that Ronald O. Perelman and Dr. Anna Chapman, through the Perelman Family Foundation, have committed more than $4 million in funding to launch the first ever research program solely dedicated to the early detection and prevention of multiple myeloma. This generous donation will seed the launch of the groundbreaking Perelman Family Foundation Early Disease Translational Research Program, part of the MMRF Prevention Project, to speed efforts toward early detection, delayed disease progression, and eventually, ultimately, prevention of this incurable disease.
“The goal of this initiative is to develop a completely new paradigm for research in to multiple myeloma, focusing on early detection and ultimately, prevention. Right now, detection of this terrible disease often comes too late. Unlike most cancers, early detection of multiple myeloma doesn’t increase a person’s chance of survival under current treatment options. The Perelman Family Foundation Early Disease Translational Research Program will support research focused on improving outcomes after early detection. With the MMRF and our university partners, we are confident that we will be able to make breakthroughs for multiple myeloma patients, and that the program will serve as a model for future initiatives,” said Dr. Anna Chapman.
- Better understanding of genomic determinants of early disease progression
- Impact of microenvironmental factors on early disease progression
- Enhancing tumor immunity in MGUS/SMM
- Multiple Myeloma Research Foundation
- Dana-Farber Cancer Institute
- Dr. Irene Ghobrial, PI
- Memorial Sloan Kettering Cancer Center
- Dr. Ola Landgren, PI
- MD Anderson Cancer Center
- Dr. Robert Orlowski, PI
- Dr. Elizabet Manasanch, PI
- Rockefeller University
- Dr. Kivanc Birsoy, PI
- NYU Langone Health's Perlmutter Cancer Center
- Dr. Gareth Morgan, PI
- Emory University
- Dr. Madhav Dhodapkar, PI
The gift from the Perelman Family Foundation provides a catalyst for essential research focused on: better understanding genomic determinants of early disease progression; how microenvironment factors influence early disease progression; and enhancing patient tumor immunity.
Perelman Family Foundation Early Disease Translational Research Program brings together six leading cancer research centers: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Rockefeller University, University of Arkansas for Medical Science, Emory University, as well as the MMRF. The studies conducted by these teams will identify novel targets and biomarkers of disease progression and enable the development of therapeutic approaches to delay or even stop progression to myeloma.